Outwit investments completed the comprehensive tender offer and became the main shareholder of the company.
Completion of very significant asset acquisition (VSA), acquisition of Yuanda Pharmaceutical (China) Co., Ltd. (formerly Wuhan Yuanda Pharmaceutical Group)
Complete the sale of very important assets, and sell the company’s original Apollo business and related assets.
Opened offer to quality shareholders at a subscription price of HK$ 0.58 per offer share on the basis of one offer share for every three existing shares held payable in full on application, and thus raised funds of HK$ 278 million
Entered into an exclusive license agreement with Swiss-based R&D company Glenmark Specialty S.A., thereby the Group being licensed to exclusively sell Ryaltrisin China for a period of 20 years
Entered into an exclusive licensing and co-development agreement with Griffith University in Australia, pursuant to which the Group obtained the global development and commercialization rights for the world-wide first developed product for the treatment of parainfluenza infection
Entered into a technology transfer agreement with Chongqing AnTi New Bio-technology Limited and obtained all rights of technical and intellectual property around the world for the world-wide first developed drug APAD
Entered into a product licensing agreement with Cloudbreak Bio-Pharmaceutical Science and Technology (Guangzhou) Co., Ltd. and CloudBreak Therapeutics LLC, and acquired approximately 6.5% interest of the enlarged share capital of Cloudbreak Pharmaceutical Inc.